Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.
2.

SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS.

Gill C, Phelan JP, Hatzipetros T, Kidd JD, Tassinari VR, Levine B, Wang MZ, Moreno A, Thompson K, Maier M, Grimm J, Gill A, Vieira FG.

Sci Rep. 2019 Apr 30;9(1):6724. doi: 10.1038/s41598-019-43164-z.

3.

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis.

Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, Vieira FG, Kulic L, Späni C, Stehle T, Perrin S, Weber M, Hock C, Nitsch RM, Grimm J.

Sci Transl Med. 2018 Dec 5;10(470). pii: eaah3924. doi: 10.1126/scitranslmed.aah3924.

PMID:
30518612
4.

CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits.

Vieira FG, Hatzipetros T, Thompson K, Moreno AJ, Kidd JD, Tassinari VR, Levine B, Perrin S, Gill A.

IBRO Rep. 2017 Mar 12;2:47-53. doi: 10.1016/j.ibror.2017.03.001. eCollection 2017 Jun.

5.

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS.

Hatzipetros T, Kidd JD, Moreno AJ, Thompson K, Gill A, Vieira FG.

J Vis Exp. 2015 Oct 6;(104). doi: 10.3791/53257.

6.

Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.

Vieira FG, Ping Q, Moreno AJ, Kidd JD, Thompson K, Jiang B, Lincecum JM, Wang MZ, De Zutter GS, Tassinari VR, Levine B, Hatzipetros T, Gill A, Perrin S.

PLoS One. 2015 Aug 19;10(8):e0135570. doi: 10.1371/journal.pone.0135570. eCollection 2015.

7.

Dexpramipexole is ineffective in two models of ALS related neurodegeneration.

Vieira FG, LaDow E, Moreno A, Kidd JD, Levine B, Thompson K, Gill A, Finkbeiner S, Perrin S.

PLoS One. 2014 Dec 19;9(12):e91608. doi: 10.1371/journal.pone.0091608. eCollection 2014.

8.

C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS.

Hatzipetros T, Bogdanik LP, Tassinari VR, Kidd JD, Moreno AJ, Davis C, Osborne M, Austin A, Vieira FG, Lutz C, Perrin S.

Brain Res. 2014 Oct 10;1584:59-72. doi: 10.1016/j.brainres.2013.10.013. Epub 2013 Oct 18.

PMID:
24141148
9.

From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis.

Lincecum JM, Vieira FG, Wang MZ, Thompson K, De Zutter GS, Kidd J, Moreno A, Sanchez R, Carrion IJ, Levine BA, Al-Nakhala BM, Sullivan SM, Gill A, Perrin S.

Nat Genet. 2010 May;42(5):392-9. doi: 10.1038/ng.557. Epub 2010 Mar 28.

PMID:
20348957
10.

Design, power, and interpretation of studies in the standard murine model of ALS.

Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, Bostrom A, Theodoss J, Al-Nakhala BM, Vieira FG, Ramasubbu J, Heywood JA.

Amyotroph Lateral Scler. 2008;9(1):4-15. doi: 10.1080/17482960701856300.

PMID:
18273714
11.

Impact of IL-1beta on flow-induced outward arterial remodeling.

Jiang Z, Berceli SA, Pfahnl CL, Wu L, Killingsworth CD, Vieira FG, Ozaki CK.

Surgery. 2004 Aug;136(2):478-82.

PMID:
15300218

Supplemental Content

Loading ...
Support Center